PEDIATRICS Vol. 94 No. 5 November 1994, pp. 719-723
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garland, J.
Right arrow Articles by Weinberg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garland, J.
Right arrow Articles by Weinberg, M.

Pulmonary Hemorrhage Risk in Infants With a Clinically Diagnosed Patent Ductus Arteriosus: A Retrospective Cohort Study

Jeffery Garland MD, SM1, Rosanne Buck BSN, CNNP2, and Michelle Weinberg MPH3

1 Joint Program in Neonatology, Harvard Medical School, Boston, MA
2 Children's Hospital, Boston, MA
3 Harvard School of Public Health, Boston, MA

Objective. To determine if an early, dinically detectable patent ductus arteriosus (FDA) was associated with pulmonary hemorrhage (PH) in infants who received rescue artificial surfactant therapy.

Methods. This retrospective cohort study of 233 low birth weight infants (le 1700 g) who received artificial surfactant therapy for respiratory distress syndrome compared antenatal and postnatal characteristics of infants with PH and without PH. Pulmonary hemorrhage was defined by an onset of bright red blood from the endotracheal tube in quantities that resulted in increased ventilatory support and a new infiltrate on a chest radiograph.

Results. Pulmonary hemorrhage occurred in 6% (15/233) of the infants. Thirty-three percent (5/15) of the infants with PH died within 14 days of the hemorrhage. Of the 15 PH, 73% occurred within 48 hours of the first surfactant dose. Pulmonary hemorrhage was more common in male infants and infants of mothers who received antibiotic therapy during labor (P le .04). Infants with PH received surfactant earlier than those without PH (P = .04). Nursery events or therapies occurring following surfactant therapy that were associated with PH included: little improvement in ventilatory efficiency index (P = .01), dopamine infusion (P = .04), and the presence of a clinically detectable PDA before, or at the time of, the PH [60% (9/15) vs 33% (71/217), P = .03]. After adjusting for severity of illness before surfactant therapy, risk of PH remained greater in infants who developed symptoms of a PDA. Dopamine support appeared to modify the association between PDA and PH.

Conclusions. In this retrospective cohort study, pulmonary hemorrhage was associated with the presence of a clinically detectable patent ductus arteriosus before, or at the time of, pulmonary hemorrhage.

Submitted on August 31, 1993
Accepted on April 8, 1994




This article has been cited by other articles:


Home page
 PediatricsHome page
K. Alfaleh, J. A. Smyth, R. S. Roberts, A. Solimano, E. V. Asztalos, B. Schmidt, and for the Trial of Indomethacin Prophylaxis in Prete
Prevention and 18-Month Outcomes of Serious Pulmonary Hemorrhage in Extremely Low Birth Weight Infants: Results From the Trial of Indomethacin Prophylaxis in Preterms
Pediatrics, February 1, 2008; 121(2): e233 - e238.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
M. Tomaszewska, E. Stork, N. M. Minich, H. Friedman, S. Berlin, and M. Hack
Pulmonary Hemorrhage: Clinical Course and Outcomes Among Very Low-Birth-Weight Infants
Arch Pediatr Adolesc Med, July 1, 1999; 153(7): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
P. B Pandit, K. O'Brien, E. Asztalos, E. Colucci, and M. S Dunn
Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1999; 81(1): 40F - 44.
[Abstract] [Full Text]